TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Endometrial Biopsy on the Outcome of In Vitro Fertilization (IVF) /Intra-Cytoplasmic Sperm Injection (ICSI) Treatment (Endoscratch): A Feasibility Pilot Study
Brief Summary: This study aims to see if taking a small sample from the lining of the womb (the 'scratch') before starting in vitro fertilization (IVF) treatment can influence the chance of getting pregnant and having a healthy, term baby.

This study also aims to explore why an embryo is not accepted or indeed rejected by the lining of the womb. This will be analysed by carefully looking at the sample taken from the lining of the womb under the microscope and analysing the levels of natural killer (NK) cells. These cells are thought to regulate the implantation process and to be altered in some women with infertility and miscarriage.


Options:
A: Arm Label: Control - Standard ART treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Test - PGS; Type: EXPERIMENTAL; Interventions: Genetic: Next Generation Sequencing after Blastocyst biopsy | Intervention Type: GENETIC; Name: Next Generation Sequencing after Blastocyst biopsy; Assigned to Arm(s): Test - PGS
B: Arm Label: local ingury; Type: ACTIVE_COMPARATOR; Interventions: Procedure: local injury | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: local injury; Assigned to Arm(s): local ingury
C: Arm Label: Endometrial biopsy arm; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial biopsy, Device: Transvaginal ultrasound | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): Endometrial biopsy arm | Intervention Type: DEVICE; Name: Transvaginal ultrasound; Assigned to Arm(s): Endometrial biopsy arm
D: Arm Label: Comprehensive Chromosome Screening; Type: EXPERIMENTAL; Interventions: Other: Comprehensive Chromosome Screening | Arm Label: No Comprehensive Chromosome Screening; Type: PLACEBO_COMPARATOR; Interventions: Other: Morphologically Best | Intervention Type: OTHER; Name: Comprehensive Chromosome Screening; Assigned to Arm(s): Comprehensive Chromosome Screening | Intervention Type: OTHER; Name: Morphologically Best; Assigned to Arm(s): No Comprehensive Chromosome Screening

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Endometrial Biopsy on the Outcome of In Vitro Fertilization (IVF) /Intra-Cytoplasmic Sperm Injection (ICSI) Treatment (Endoscratch): A Feasibility Pilot Study
Brief Summary: This study aims to see if taking a small sample from the lining of the womb (the 'scratch') before starting in vitro fertilization (IVF) treatment can influence the chance of getting pregnant and having a healthy, term baby.

This study also aims to explore why an embryo is not accepted or indeed rejected by the lining of the womb. This will be analysed by carefully looking at the sample taken from the lining of the womb under the microscope and analysing the levels of natural killer (NK) cells. These cells are thought to regulate the implantation process and to be altered in some women with infertility and miscarriage.


Options:
A: Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): N/A
B: Arm Label: atosiban; Type: EXPERIMENTAL; Interventions: Drug: atosiban | Arm Label: 0.9% salain; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% saline | Intervention Type: DRUG; Name: atosiban; Assigned to Arm(s): atosiban | Intervention Type: DRUG; Name: 0.9% saline; Assigned to Arm(s): 0.9% salain
C: Arm Label: Atosiban used before embryo transfer; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban used before embryo transfer
D: Arm Label: Endometrial biopsy arm; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial biopsy, Device: Transvaginal ultrasound | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): Endometrial biopsy arm | Intervention Type: DEVICE; Name: Transvaginal ultrasound; Assigned to Arm(s): Endometrial biopsy arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Application for Self-Monitoring of Cardiovascular Risk
Brief Summary: Patients who recently suffered a heart attack will use a smart-phone/computer application during cardiac rehabilitation to reduce their risk of a future attack, their re-hospitalizations, their cost of care, and increase their quality of life.


Options:
A: Arm Label: Self Monitoring of Software Application; Type: OTHER; Interventions: Device: Self Monitoring Software Application | Arm Label: No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Self Monitoring Software Application; Assigned to Arm(s): Self Monitoring of Software Application
B: Arm Label: Medication text message; Type: EXPERIMENTAL; Interventions: Behavioral: Text message reminder for medication adherence | Arm Label: Exercise text message; Type: EXPERIMENTAL; Interventions: Behavioral: Text message reminder for exercise regimen | Arm Label: Usual care, medication adherence; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care, exercise regimen; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text message reminder for medication adherence; Assigned to Arm(s): Medication text message | Intervention Type: BEHAVIORAL; Name: Text message reminder for exercise regimen; Assigned to Arm(s): Exercise text message
C: Arm Label: Homebased cardiac rehabilitation program; Type: EXPERIMENTAL; Interventions: Device: Homebased cardiac rehabilitation program, Other: Traditional cardiac rehabilitation program | Arm Label: Traditional cardiac rehabilitation; Type: OTHER; Interventions: Other: Traditional cardiac rehabilitation program | Intervention Type: DEVICE; Name: Homebased cardiac rehabilitation program; Assigned to Arm(s): Homebased cardiac rehabilitation program | Intervention Type: OTHER; Name: Traditional cardiac rehabilitation program; Assigned to Arm(s): Homebased cardiac rehabilitation program, Traditional cardiac rehabilitation
D: Arm Label: PATHway; Type: EXPERIMENTAL; Interventions: Behavioral: PATHway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PATHway; Assigned to Arm(s): PATHway

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Application for Self-Monitoring of Cardiovascular Risk
Brief Summary: Patients who recently suffered a heart attack will use a smart-phone/computer application during cardiac rehabilitation to reduce their risk of a future attack, their re-hospitalizations, their cost of care, and increase their quality of life.


Options:
A: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: vCRP; Type: EXPERIMENTAL; Interventions: Behavioral: vCRP | Intervention Type: BEHAVIORAL; Name: vCRP; Assigned to Arm(s): vCRP
B: Arm Label: Family-Centered Empowerment Model; Type: EXPERIMENTAL; Interventions: Other: Family-centered empowerment model | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Family-centered empowerment model; Assigned to Arm(s): Family-Centered Empowerment Model | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Self Monitoring of Software Application; Type: OTHER; Interventions: Device: Self Monitoring Software Application | Arm Label: No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Self Monitoring Software Application; Assigned to Arm(s): Self Monitoring of Software Application
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Daily feedback | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive, Behavioral: Daily feedback | Intervention Type: BEHAVIORAL; Name: Financial incentive; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Daily feedback; Assigned to Arm(s): Control, Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis
Brief Summary: The purpose of this study is to compare the incidences of GVHD and viral infections in haploidentical hematopoietic stem cell transplant recipients receiving different dose of antithymocyte globulin (ATG) for acute graft-versus-host disease(aGVHD) prophylaxis. Our first objective was to investigate the optimal dose of ATG for aGVHD and second object was to evaluate the effect of different dose of ATG on post-transplant viral infection.


Options:
A: Arm Label: ATG 7.5mg/kg; Type: EXPERIMENTAL; Interventions: Drug: ATG | Arm Label: ATG 10mg/kg; Type: EXPERIMENTAL; Interventions: Drug: ATG | Intervention Type: DRUG; Name: ATG; Assigned to Arm(s): ATG 10mg/kg, ATG 7.5mg/kg
B: Arm Label: ATLG group; Type: N/A; Interventions: N/A | Arm Label: no ATLG group; Type: N/A; Interventions: N/A
C: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Arm Label: Best Available Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Extracorporeal photopheresis (ECP), Drug: Low-dose methotrexate (MTX), Drug: Mycophenolate mofetil (MMF), Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Drug: Infliximab, Drug: Rituximab, Drug: Pentostatin, Drug: Imatinib, Drug: Ibrutinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib | Intervention Type: DRUG; Name: Extracorporeal photopheresis (ECP); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Low-dose methotrexate (MTX); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Imatinib; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Best Available Therapy
D: Arm Label: A; Type: OTHER; Interventions: Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin) | Arm Label: B; Type: OTHER; Interventions: Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin) | Intervention Type: DRUG; Name: ATG FRESENIUS (Anti-Lymphocyte-Globulin); Assigned to Arm(s): A | Intervention Type: DRUG; Name: ATG FRESENIUS (Anti-Lymphocyte-Globulin); Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of a Task-oriented Circuit Training Associated With Transcranial Direct Current Stimulation (tDCS) for Gait Improvement in Chronic Stroke Patients . A Randomized Controlled Trial
Brief Summary: Stroke is one of the major causes of disability in the Western world. Initially gait is the most affected function, 80% of patients lose this ability.

Rehabilitation in stroke patients improves walking abilities in terms of gait and related gait activities, though six months after stroke many patients are significantly disabled.

Recently, a prospective study of 205 stroke patients showed that approximately 21% of patients have a significant decrease of mobility between the first and the third year after stroke. The main finding showed that inactivity was the most important factor for the mobility decline.

Evidence about effects of direct current brain stimulation on motor recovery function of lower limb are still little, some show that quadriceps strength after stimulation of damaged M1 area increased. Another study where tDCS was associated with robotic gait training did not report any effect compared to treatment alone. It is necessary to define if a different dosage of stimulation or the association of tDCS with gait training can improve walking and if further studies are required to investigate their effectiveness.

The aim of this clinical trial is to test the possibility of gait improvement through the association of tDCS with a specific task-oriented circuit training for walking abilities, balance and mobility.


Options:
A: Arm Label: real tDCS + TOCT; Type: EXPERIMENTAL; Interventions: Device: real tDCS + TOCT | Arm Label: sham tDCS + TOCT; Type: ACTIVE_COMPARATOR; Interventions: Device: sham tDCS + TOCT | Intervention Type: DEVICE; Name: sham tDCS + TOCT; Assigned to Arm(s): sham tDCS + TOCT | Intervention Type: DEVICE; Name: real tDCS + TOCT; Assigned to Arm(s): real tDCS + TOCT
B: Arm Label: tDCS and occupational therapy; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: Sham and occupational therapy; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): tDCS and occupational therapy | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham and occupational therapy
C: Arm Label: Early mobilization; Type: EXPERIMENTAL; Interventions: Other: Early mobilization | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early mobilization; Assigned to Arm(s): Early mobilization
D: Arm Label: usual management; Type: OTHER; Interventions: Other: no physical activity | Arm Label: physical training; Type: EXPERIMENTAL; Interventions: Other: physical activity | Intervention Type: OTHER; Name: no physical activity; Assigned to Arm(s): usual management | Intervention Type: OTHER; Name: physical activity; Assigned to Arm(s): physical training

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-component Intervention to Increase Physical Activity in Preschool Children
Brief Summary: The study addresses a critical public health problem, childhood obesity, by testing a physical activity intervention in the types of preschools that millions of children attend. Information gained in this study may lead to adoption of preschool policies and instructional practices that increase physical activity and reduce the risk of obesity in preschool children.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Go NAP SACC | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Go NAP SACC; Assigned to Arm(s): Intervention group
B: Arm Label: Nutrition and Physical Activity Training; Type: EXPERIMENTAL; Interventions: Behavioral: NAP-SACC Child Care Wellness Program | Arm Label: Delayed Intervention Group; Type: OTHER; Interventions: Behavioral: NAP-SACC Child Care Wellness Program | Intervention Type: BEHAVIORAL; Name: NAP-SACC Child Care Wellness Program; Assigned to Arm(s): Delayed Intervention Group, Nutrition and Physical Activity Training
C: Arm Label: intervention 1; Type: EXPERIMENTAL; Interventions: Behavioral: classroom curriculum, Behavioral: In-service training for Head Start teachers/aides, Behavioral: Training for Head Start food service, Behavioral: Family intervention component, Behavioral: Food source, Behavioral: Health care providers, Behavioral: CHILE Head Start Intervention | Arm Label: control 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: classroom curriculum; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: In-service training for Head Start teachers/aides; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Training for Head Start food service; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Family intervention component; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Food source; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Health care providers; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: CHILE Head Start Intervention; Assigned to Arm(s): intervention 1
D: Arm Label: Physical Activity Preschool Intervention; Type: EXPERIMENTAL; Interventions: Other: Physical Activity Preschool Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physical Activity Preschool Intervention; Assigned to Arm(s): Physical Activity Preschool Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HALT Progression of Polycystic Kidney Disease Study B
Brief Summary: The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two simultaneous multicenter randomized clinical trials targeting different levels of kidney function: 1) early disease defined by GFR \>60 mL/min/1.73 m2 (Study A); and 2) moderately advanced disease defined by GFR 25-60 mL/min/1.73 m2 (Study B). Participants will be recruited and enrolled, either to Study A or B, over the first three years. Participants enrolled in Study B will be followed for five-to-eight years, with the average length of follow-up being six and a half years.

Combination therapy will use angiotensin-converting-enzyme inhibitor (ACE-I) and an angiotensin-receptor blocker (ARB). Monotherapy will use ACE-I alone.


Options:
A: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
B: Arm Label: ACE-I + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo | Arm Label: ACE-I + ARB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): ACE-I + ARB, ACE-I + placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): ACE-I + ARB | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): ACE-I + placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: OPC-41061 | Intervention Type: DRUG; Name: OPC-41061; Assigned to Arm(s): 1
D: Arm Label: Tolvaptan 45/15 mg/day orally for up to 4 years; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Tolvaptan 60/30 mg/day orally for up to 4 years; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan 45/15 mg/day orally for up to 4 years, Tolvaptan 60/30 mg/day orally for up to 4 years

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy
Brief Summary: In this study the study team proposes to investigate the efficacy of albuterol on motor function of individuals with Late Onset Pompe Disease (LOPD) who are receiving enzyme replacement therapy, given albuterol was well-tolerated in patients with Late Onset Pompe Disease.


Options:
A: Arm Label: Alglucosidase Alfa/Alglucosidase Alfa; Type: EXPERIMENTAL; Interventions: Biological: alglucosidase alfa | Arm Label: Placebo/Alglucosidase Alfa; Type: EXPERIMENTAL; Interventions: Biological: alglucosidase alfa | Intervention Type: BIOLOGICAL; Name: alglucosidase alfa; Assigned to Arm(s): Alglucosidase Alfa/Alglucosidase Alfa, Placebo/Alglucosidase Alfa
B: Arm Label: Cipaglucosidase Alfa/Miglustat; Type: EXPERIMENTAL; Interventions: Biological: Cipaglucosidase Alfa, Drug: Miglustat | Arm Label: Alglucosidase Alfa/Placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: Alglucosidase Alfa, Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Cipaglucosidase Alfa; Assigned to Arm(s): Cipaglucosidase Alfa/Miglustat | Intervention Type: DRUG; Name: Miglustat; Assigned to Arm(s): Cipaglucosidase Alfa/Miglustat | Intervention Type: BIOLOGICAL; Name: Alglucosidase Alfa; Assigned to Arm(s): Alglucosidase Alfa/Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alglucosidase Alfa/Placebo
C: Arm Label: alglucosidase alfa; Type: ACTIVE_COMPARATOR; Interventions: Biological: alglucosidase alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: alglucosidase alfa; Assigned to Arm(s): alglucosidase alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Albuterol; Type: EXPERIMENTAL; Interventions: Drug: Albuterol | Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Albuterol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RECALL: Retaining Cognition While Avoiding Late-Life Depression
Brief Summary: This study will adapt Problem Solving Therapy (PST) for individuals with mild cognitive impairment (MCI) as an intervention for preventing major depression (DEP). PST will be modified so as to be provided to both MCI probands as well as their support person. The primary aim is to examine the effectiveness of PST in individuals with MCI and the support person, at preventing DEP over 12 mos. in MCI probands. We also will examine the effect of exercise on preventing depression.


Options:
A: Arm Label: PATH; Type: EXPERIMENTAL; Interventions: Behavioral: PATH | Arm Label: ST-CI; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ST-CI | Intervention Type: BEHAVIORAL; Name: PATH; Assigned to Arm(s): PATH | Intervention Type: BEHAVIORAL; Name: ST-CI; Assigned to Arm(s): ST-CI
B: Arm Label: Behavior Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation (BA) | Arm Label: Supportive Therapy (ST); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Therapy (ST) | Intervention Type: BEHAVIORAL; Name: Behavioral Activation (BA); Assigned to Arm(s): Behavior Activation | Intervention Type: BEHAVIORAL; Name: Supportive Therapy (ST); Assigned to Arm(s): Supportive Therapy (ST)
C: Arm Label: Cognitive Behavioral Therapy (CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Comprehensive, CBT-based, multi-component treatment | Arm Label: Treatment as usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Comprehensive, CBT-based, multi-component treatment; Assigned to Arm(s): Cognitive Behavioral Therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual (TAU)
D: Arm Label: Problem Solving Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Problem Solving Therapy | Arm Label: Problem Solving Therapy + Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Problem Solving Therapy + Exercise | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): Problem Solving Therapy | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy + Exercise; Assigned to Arm(s): Problem Solving Therapy + Exercise | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care

Answer: D